Precigen’s (PGEN) Buy Rating Reaffirmed at HC Wainwright

Precigen (NASDAQ:PGEN)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $6.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 235.20% from the stock’s current price.

Separately, JMP Securities restated a “market outperform” rating and issued a $5.00 price target on shares of Precigen in a report on Tuesday, January 14th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat, Precigen currently has a consensus rating of “Hold” and an average price target of $7.00.

Precigen Trading Up 7.2 %

PGEN stock opened at $1.79 on Thursday. The company’s 50-day moving average price is $1.58 and its 200 day moving average price is $1.14. Precigen has a 52 week low of $0.65 and a 52 week high of $2.17. The company has a market cap of $524.24 million, a P/E ratio of -3.25 and a beta of 1.58.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets acquired a new position in shares of Precigen in the fourth quarter worth $27,000. Envestnet Asset Management Inc. lifted its holdings in shares of Precigen by 29.0% during the 4th quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 5,915 shares during the period. Boothbay Fund Management LLC acquired a new position in shares of Precigen in the 4th quarter valued at $35,000. Stifel Financial Corp grew its position in Precigen by 94.9% during the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 15,680 shares during the period. Finally, RPO LLC purchased a new stake in shares of Precigen during the 4th quarter worth about $47,000. 33.51% of the stock is owned by hedge funds and other institutional investors.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.